Could targeted therapies hold the key to reducing cancer side effects? 2024 Industrial Fellow Harry Palmer shares his research on targeted cancer therapies in Drug Discovery World Harry explores the revolutionary potential of antibody-drug conjugates (ADCs), which combine the targeting precision of antibodies with the effectiveness of chemotherapy. This approach offers improved outcomes and reduced side effects by selectively attacking cancer cells while sparing healthy ones. His research focuses on optimising ADCs to pave the way for more personalised and effective treatments. Harry is pursuing his Industrial Fellowship with GSK and the University of Strathclyde, where he’s advancing this cutting-edge approach to combat cancer and improve patient care. Have a read in DDW’s Winter issue (pages 40-41) ➡️ https://lnkd.in/eewYJ7We
Royal Commission for the Exhibition of 1851’s Post
More Relevant Posts
-
💡TCRm antibodies are revolutionizing cancer immunotherapy by combining T-cell receptor precision with antibody versatility, enabling the targeting of a wider range of intracellular antigens. 💡These antibodies can recognize antigens presented by MHC molecules, achieving subnanomolar affinity for greater therapeutic impact. With mechanisms like ADCC, CDC, and peptide-MHC targeting, TCRm antibodies enhance tumor cell destruction. 💡They also provide antibody-like stability and a long half-life, while being easier to manufacture than traditional TCR-based therapies, making them scalable for large-scale application. Nona Biosciences is at the forefront of this innovation, advancing cancer treatment with highly specific and promising TCRm designs. Learn more: https://lnkd.in/eT-_VkKp
-
🔬 The Evolution of Antibody-Drug Conjugates (ADCs) in Cancer Therapeutics 🧬 As we mark 40 years of ADC development, it's time to reflect on the progress and challenges in this promising field of cancer treatment. Key Highlights: • 11 FDA-approved ADCs, with 200+ in clinical trials • Combining tumor-targeting antibodies with potent chemotherapy payloads • Challenges include managing toxicities and identifying predictive biomarkers Recent Breakthroughs: ✅ Expanded use in earlier treatment lines ✅ Novel combinations with immunotherapy ✅ Innovations in design: bispecific antibodies, site-specific conjugation, and novel linker chemistries The Future of ADCs: 🔍 Refining biomarker strategies 🧪 Exploring diverse payload classes 🔬 Deepening our understanding of ADC pharmacology While the initial "magic bullet" concept has evolved, ADCs have firmly established themselves as a crucial modality in cancer treatment. The ongoing challenge? Balancing efficacy and toxicity to unlock their full potential. What are your thoughts on the future of ADCs in cancer therapy? CancerResearch #Oncology #DrugDevelopment #Biotechnology #ADCs
-
🔬 The Evolution of Antibody-Drug Conjugates (ADCs) in Cancer Therapeutics 🧬 As we mark 40 years of ADC development, it's time to reflect on the progress and challenges in this promising field of cancer treatment. Key Highlights: • 11 FDA-approved ADCs, with 200+ in clinical trials • Combining tumor-targeting antibodies with potent chemotherapy payloads • Challenges include managing toxicities and identifying predictive biomarkers Recent Breakthroughs: ✅ Expanded use in earlier treatment lines ✅ Novel combinations with immunotherapy ✅ Innovations in design: bispecific antibodies, site-specific conjugation, and novel linker chemistries The Future of ADCs: 🔍 Refining biomarker strategies 🧪 Exploring diverse payload classes 🔬 Deepening our understanding of ADC pharmacology While the initial "magic bullet" concept has evolved, ADCs have firmly established themselves as a crucial modality in cancer treatment. The ongoing challenge? Balancing efficacy and toxicity to unlock their full potential. What are your thoughts on the future of ADCs in cancer therapy? CancerResearch #Oncology #DrugDevelopment #Biotechnology #ADCs
-
🔬 The Evolution of Antibody-Drug Conjugates (ADCs) in Cancer Therapeutics 🧬 As we mark 40 years of ADC development, it's time to reflect on the progress and challenges in this promising field of cancer treatment. Key Highlights: • 11 FDA-approved ADCs, with 200+ in clinical trials • Combining tumor-targeting antibodies with potent chemotherapy payloads • Challenges include managing toxicities and identifying predictive biomarkers Recent Breakthroughs: ✅ Expanded use in earlier treatment lines ✅ Novel combinations with immunotherapy ✅ Innovations in design: bispecific antibodies, site-specific conjugation, and novel linker chemistries The Future of ADCs: 🔍 Refining biomarker strategies 🧪 Exploring diverse payload classes 🔬 Deepening our understanding of ADC pharmacology While the initial "magic bullet" concept has evolved, ADCs have firmly established themselves as a crucial modality in cancer treatment. The ongoing challenge? Balancing efficacy and toxicity to unlock their full potential. What are your thoughts on the future of ADCs in cancer therapy? CancerResearch #Oncology #DrugDevelopment #Biotechnology #ADCs
-
🔬 The Evolution of Antibody-Drug Conjugates (ADCs) in Cancer Therapeutics 🧬 As we mark 40 years of ADC development, it's time to reflect on the progress and challenges in this promising field of cancer treatment. Key Highlights: • 11 FDA-approved ADCs, with 200+ in clinical trials • Combining tumor-targeting antibodies with potent chemotherapy payloads • Challenges include managing toxicities and identifying predictive biomarkers Recent Breakthroughs: ✅ Expanded use in earlier treatment lines ✅ Novel combinations with immunotherapy ✅ Innovations in design: bispecific antibodies, site-specific conjugation, and novel linker chemistries The Future of ADCs: 🔍 Refining biomarker strategies 🧪 Exploring diverse payload classes 🔬 Deepening our understanding of ADC pharmacology While the initial "magic bullet" concept has evolved, ADCs have firmly established themselves as a crucial modality in cancer treatment. The ongoing challenge? Balancing efficacy and toxicity to unlock their full potential. What are your thoughts on the future of ADCs in cancer therapy? CancerResearch #Oncology #DrugDevelopment #Biotechnology #ADCs
-
🔬 The Evolution of Antibody-Drug Conjugates (ADCs) in Cancer Therapeutics 🧬 As we mark 40 years of ADC development, it's time to reflect on the progress and challenges in this promising field of cancer treatment. Key Highlights: • 11 FDA-approved ADCs, with 200+ in clinical trials • Combining tumor-targeting antibodies with potent chemotherapy payloads • Challenges include managing toxicities and identifying predictive biomarkers Recent Breakthroughs: ✅ Expanded use in earlier treatment lines ✅ Novel combinations with immunotherapy ✅ Innovations in design: bispecific antibodies, site-specific conjugation, and novel linker chemistries The Future of ADCs: 🔍 Refining biomarker strategies 🧪 Exploring diverse payload classes 🔬 Deepening our understanding of ADC pharmacology While the initial "magic bullet" concept has evolved, ADCs have firmly established themselves as a crucial modality in cancer treatment. The ongoing challenge? Balancing efficacy and toxicity to unlock their full potential. What are your thoughts on the future of ADCs in cancer therapy? CancerResearch #Oncology #DrugDevelopment #Biotechnology #ADCs
-
🔬 The Evolution of Antibody-Drug Conjugates (ADCs) in Cancer Therapeutics 🧬 As we mark 40 years of ADC development, it's time to reflect on the progress and challenges in this promising field of cancer treatment. Key Highlights: • 11 FDA-approved ADCs, with 200+ in clinical trials • Combining tumor-targeting antibodies with potent chemotherapy payloads • Challenges include managing toxicities and identifying predictive biomarkers Recent Breakthroughs: ✅ Expanded use in earlier treatment lines ✅ Novel combinations with immunotherapy ✅ Innovations in design: bispecific antibodies, site-specific conjugation, and novel linker chemistries The Future of ADCs: 🔍 Refining biomarker strategies 🧪 Exploring diverse payload classes 🔬 Deepening our understanding of ADC pharmacology While the initial "magic bullet" concept has evolved, ADCs have firmly established themselves as a crucial modality in cancer treatment. The ongoing challenge? Balancing efficacy and toxicity to unlock their full potential. What are your thoughts on the future of ADCs in cancer therapy? CancerResearch #Oncology #DrugDevelopment #Biotechnology #ADCs
-
Matching top talent to meaningful careers at Parexel #withheart 💜 Recruiting positions for Latam
🔬 The Evolution of Antibody-Drug Conjugates (ADCs) in Cancer Therapeutics 🧬 As we mark 40 years of ADC development, it's time to reflect on the progress and challenges in this promising field of cancer treatment. Key Highlights: • 11 FDA-approved ADCs, with 200+ in clinical trials • Combining tumor-targeting antibodies with potent chemotherapy payloads • Challenges include managing toxicities and identifying predictive biomarkers Recent Breakthroughs: ✅ Expanded use in earlier treatment lines ✅ Novel combinations with immunotherapy ✅ Innovations in design: bispecific antibodies, site-specific conjugation, and novel linker chemistries The Future of ADCs: 🔍 Refining biomarker strategies 🧪 Exploring diverse payload classes 🔬 Deepening our understanding of ADC pharmacology While the initial "magic bullet" concept has evolved, ADCs have firmly established themselves as a crucial modality in cancer treatment. The ongoing challenge? Balancing efficacy and toxicity to unlock their full potential. What are your thoughts on the future of ADCs in cancer therapy? CancerResearch #Oncology #DrugDevelopment #Biotechnology #ADCs
-
🔬 The Evolution of Antibody-Drug Conjugates (ADCs) in Cancer Therapeutics 🧬 As we mark 40 years of ADC development, it's time to reflect on the progress and challenges in this promising field of cancer treatment. Key Highlights: • 11 FDA-approved ADCs, with 200+ in clinical trials • Combining tumor-targeting antibodies with potent chemotherapy payloads • Challenges include managing toxicities and identifying predictive biomarkers Recent Breakthroughs: ✅ Expanded use in earlier treatment lines ✅ Novel combinations with immunotherapy ✅ Innovations in design: bispecific antibodies, site-specific conjugation, and novel linker chemistries The Future of ADCs: 🔍 Refining biomarker strategies 🧪 Exploring diverse payload classes 🔬 Deepening our understanding of ADC pharmacology While the initial "magic bullet" concept has evolved, ADCs have firmly established themselves as a crucial modality in cancer treatment. The ongoing challenge? Balancing efficacy and toxicity to unlock their full potential. What are your thoughts on the future of ADCs in cancer therapy? CancerResearch #Oncology #DrugDevelopment #Biotechnology #ADCs
-
🔬 The Evolution of Antibody-Drug Conjugates (ADCs) in Cancer Therapeutics 🧬 As we mark 40 years of ADC development, it's time to reflect on the progress and challenges in this promising field of cancer treatment. Key Highlights: • 11 FDA-approved ADCs, with 200+ in clinical trials • Combining tumor-targeting antibodies with potent chemotherapy payloads • Challenges include managing toxicities and identifying predictive biomarkers Recent Breakthroughs: ✅ Expanded use in earlier treatment lines ✅ Novel combinations with immunotherapy ✅ Innovations in design: bispecific antibodies, site-specific conjugation, and novel linker chemistries The Future of ADCs: 🔍 Refining biomarker strategies 🧪 Exploring diverse payload classes 🔬 Deepening our understanding of ADC pharmacology While the initial "magic bullet" concept has evolved, ADCs have firmly established themselves as a crucial modality in cancer treatment. The ongoing challenge? Balancing efficacy and toxicity to unlock their full potential. What are your thoughts on the future of ADCs in cancer therapy? CancerResearch #Oncology #DrugDevelopment #Biotechnology #ADCs
